Education
About Us
Working with TipRanks
Follow Us
Genscript Biotech (GNNSF)
OTHER OTC:GNNSF
Total Valuation
Genscript Biotech has a market cap or net worth of $4.66B. The enterprise value is $6.00B.
Market Cap$4.66B
Enterprise Value$6.00B
Share Statistics
Genscript Biotech has 2,178,855,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,178,855,200
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Genscript Biotech’s return on equity (ROE) is 0.69 and return on invested capital (ROIC) is 0.19%.
Return on Equity (ROE)0.69
Return on Assets (ROA)0.56
Return on Invested Capital (ROIC)0.19%
Return on Capital Employed (ROCE)<0.01
Revenue Per Employee106.77K
Profits Per Employee531.95K
Employee Count5,568
Asset Turnover0.11
Inventory Turnover10.37
Valuation Ratios
The current PE Ratio of Genscript Biotech is 0.93. Genscript Biotech’s PEG ratio is 0.76.
PE Ratio0.93
PS Ratio0.00
PB Ratio6.60
Price to Fair Value0.64
Price to FCF-19.83
Price to Operating Cash Flow-55.44
PEG Ratio0.76
Income Statement
In the last 12 months, Genscript Biotech had revenue of 594.49M and earned 2.96B in profits. Earnings per share was -0.03.
Revenue594.49M
Gross Profit272.13M
Operating Income9.28M
Pretax Income-170.80M
Net Income2.96B
EBITDA70.43M
Earnings Per Share (EPS)-0.03
Cash Flow
In the last 12 months, operating cash flow was 79.86M and capital expenditures -134.03M, giving a free cash flow of -54.17M billion.
Operating Cash Flow79.86M
Free Cash Flow-54.17M
Free Cash Flow per Share-0.02
Dividends & Yields
Genscript Biotech pays an annual dividend of $0.012, resulting in a dividend yield of ―
Dividend Per Share$0.012
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.32
52-Week Price Change86.44%
50-Day Moving Average1.45
200-Day Moving Average1.47
Relative Strength Index (RSI)96.98
Average Volume (3m)210.00
Important Dates
Genscript Biotech upcoming earnings date is Sep 8, 2025, TBA Not Confirmed.
Last Earnings DateMar 12, 2025
Next Earnings DateSep 8, 2025
Ex-Dividend DateJun 18, 2020
Financial Position
Genscript Biotech as a current ratio of 2.72, with Debt / Equity ratio of 34.62%
Current Ratio2.72
Quick Ratio2.62
Debt to Market Cap0.24
Net Debt to EBITDA8.40
Interest Coverage Ratio1.16
Taxes
In the past 12 months, Genscript Biotech has paid 2.98M in taxes.
Income Tax2.98M
Effective Tax Rate-0.02
Enterprise Valuation
Genscript Biotech EV to EBITDA ratio is 47.57, with an EV/FCF ratio of -46.35.
EV to Sales5.64
EV to EBITDA47.57
EV to Free Cash Flow-46.35
EV to Operating Cash Flow44.28
Balance Sheet
Genscript Biotech has $621.18M in cash and marketable securities with $723.74M in debt, giving a net cash position of $102.55M billion.
Cash & Marketable Securities$621.18M
Total Debt$723.74M
Net Cash$102.55M
Net Cash Per Share$0.05
Tangible Book Value Per Share$1.98
Margins
Gross margin is 48.60%, with operating margin of 1.56%, and net profit margin of 498.22%.
Gross Margin48.60%
Operating Margin1.56%
Pretax Margin-28.73%
Net Profit Margin498.22%
EBITDA Margin11.85%
EBIT Margin1.56%
Analyst Forecast
The average price target for Genscript Biotech is $2.79, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$2.79
Price Target Upside26.82% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―